A POOLED ANALYSIS OF THE IMPACT OF AGE ON OUTCOMES IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE

被引：0

作者：

Palumbo, A. ^{[1
]}

Dimopoulos, M. A. ^{[2
]}

Richardson, P. G. ^{[3
]}

Siegel, D. S. ^{[4
]}

Cavo, M. ^{[5
]}

Corradini, P. ^{[6
]}

Weisel, K. C. ^{[7
]}

Delforge, M. ^{[8
]}

Chen, C. ^{[9
]}

Goldschmidt, H. ^{[10
,11
]}

Jagannath, S. ^{[12
]}

Lockhorst, H. M. ^{[13
]}

Moreau, P. ^{[14
]}

Plesner, T.

Sternas, L. ^{[16
]}

Peluso, T. ^{[15
,17
]}

Hong, K. ^{[16
]}

Herring, J. ^{[16
]}

Yu, X. ^{[16
]}

Zaki, M. H. ^{[16
]}

San Miguel, J. ^{[18
]}

机构：

[1] Univ Turino, Turin, Italy

[2] Univ Athens, Athens, Greece

[3] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA

[4] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[5] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[6] Univ Milan, Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[7] Univ Hosp Tuebingen, Tubingen, Germany

[8] Univ Hosp Leuven, Leuven, Belgium

[9] Princess Margaret Hosp, Toronto, ON, Canada

[10] Univ Hosp Heidelberg, Heidelberg, Germany

[11] German Canc Res Ctr, Heidelberg, Germany

[12] Mt Sinai Hosp, New York, NY 10029 USA

[13] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[14] Univ Hosp Hotel Dieu, Nantes, France

[15] Univ Southern Denmark, Dept Hematol, Ctr Little Belt, Vejle Hosp, Vejle, Denmark

[16] Celgene Corp, Summit, NJ USA

[17] Celgene Int Sarl, Boudry, Switzerland

[18] Univ Navarra Clin, CIMA, IDISNA, Pamplona, Spain

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

E1295

引用

页码：535 / 536

页数：2

共 50 条

[21] Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma
Seok Jin Kim
Danbee Kang
Yong Park
Yeung-Chul Mun
Kihyun Kim
Jin Seok Kim
Chang-Ki Min
Juhee Cho
Supportive Care in Cancer, 2021, 29 : 4969 - 4977
[22] Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma
Kim, Seok Jin
Kang, Danbee
Park, Yong
Mun, Yeung-Chul
Kim, Kihyun
Kim, Jin Seok
Min, Chang-Ki
Cho, Juhee
SUPPORTIVE CARE IN CANCER, 2021, 29 (09) : 4969 - 4977
[23] Continuous low-dose dexamethasone in relapsed or refractory multiple myeloma
Tiplady, CW
Summerfield, GP
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (01) : 381 - 381
[24] MM-011: A Phase 2 Study of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma in Japan
Hagiwara, Shotaro
Okamoto, Shinichiro
Matsue, Kosei
Iida, Shinsuke
Sunami, Kazutaka
Komeno, Takuya
Suzuki, Kenshi
Ando, Kiyoshi
Taniwaki, Masafumi
Tobinai, Kensei
Chou, Takaaki
Kaneko, Hitomi
Iwasaki, Hiromi
Uemura, Chie
Tamakoshi, Hiromi
Zaki, Mohamed H.
Doerr, Thomas
Kuroda, Yoshiaki
Ichinohe, Tatsuo
BLOOD, 2015, 126 (23)
[25] Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
Dimopoulos, Meletios
Weisel, Katja
van de Donk, Niels W. C. J.
Ramasamy, Karthik
Gamberi, Barbara
Streetly, Matthew
Offidani, Massimo
Bridoux, Frank
de la Rubia, Javier
Mateos, Maria-Victoria
Ardizzoia, Antonio
Kueenburg, Elisabeth
Collins, Shona
Di Micco, Antonia
Rosettani, Barbara
Li, Yan
Bacon, Pamela
Sonneveld, Pieter
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (20) : 2035 - +
[26] Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma
Kobayashi, Tsutomu
Kuroda, Junya
Fuchida, Shin-ichi
Kaneko, Hitomi
Yagi, Hideo
Shibayama, Hirohiko
Tanaka, Hirokazu
Kosugi, Satoru
Uoshima, Nobuhiko
Kobayashi, Masayuki
Adachi, Yoko
Ohta, Kensuke
Ishii, Kazuyoshi
Uchiyama, Hitoji
Matsuda, Mitsuhiro
Nakatani, Eiji
Tsudo, Mitsuru
Shimazaki, Chihiro
Takaori-Kondo, Akifumi
Nomura, Shosaku
Matsumura, Itaru
Taniwaki, Masafumi
Kanakura, Yuzuru
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (01) : 37 - 45
[27] Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma
Tsutomu Kobayashi
Junya Kuroda
Shin-ichi Fuchida
Hitomi Kaneko
Hideo Yagi
Hirohiko Shibayama
Hirokazu Tanaka
Satoru Kosugi
Nobuhiko Uoshima
Masayuki Kobayashi
Yoko Adachi
Kensuke Ohta
Kazuyoshi Ishii
Hitoji Uchiyama
Mitsuhiro Matsuda
Eiji Nakatani
Mitsuru Tsudo
Chihiro Shimazaki
Akifumi Takaori-Kondo
Shosaku Nomura
Itaru Matsumura
Masafumi Taniwaki
Yuzuru Kanakura
International Journal of Hematology, 2015, 101 : 37 - 45
[28] Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
Del Giudice, Maria Livia
Gozzetti, Alessandro
Antonioli, Elisabetta
Orciuolo, Enrico
Ghio, Francesco
Ciofini, Sara
Candi, Veronica
Fontanelli, Giulia
Attucci, Irene
Formica, Giuseppe
Bocchia, Monica
Galimberti, Sara
Petrini, Mario
Buda, Gabriele
MEDICINA-LITHUANIA, 2021, 57 (09):
[29] ANALYSIS OF PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE PHASE 3B STRATUS TRIAL (MM-010)
Weisel, K.
Dimopoulos, M. A.
Palumbo, A.
Corradini, P.
Cavo, M.
Delforge, M.
Ocio, E. M.
Vacca, A.
Hansson, M.
Blanchard, M.
Milller, N.
Peluso, T.
Sternas, L.
Zaki, M.
Moreau, P.
HAEMATOLOGICA, 2015, 100 : 89 - 90
[30] Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) for Relapsed and Refractory Multiple Myeloma (RRMM): Results from a Pharmacoeconomic Evaluation
Schey, Steve
Dhanasiri, Sujith
Lee, Dawn
Sternas, Lars
Yu, Xin
Zaki, Mohamed H.
Elvidge, Jamie
O'Dwyer, Michael
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →